# Partner Therapeutics

> Partner Therapeutics is a private, integrated biotechnology company developing, manufacturing and commercializing medicines for cancer and other serious diseases, with additional work in health security and critical care. Its portfolio includes Leukine, U.S. commercialization of Bizengri for NRG1 fusion-positive cancers, and EU-authorized Imreplys for acute radiation injury.

- **Founded:** 2017
- **Headquarters:** Lexington, United States
- **Founders:** Robert Mulroy (Co-founder and Chief Executive Officer), Debasish Roychowdhury (Co-founder and Chief Technology Officer; Chief Medical Officer at launch)
- **Products:** Leukine (sargramostim), Bizengri (zenocutuzumab-zbco), Imreplys (sargramostim), PTx Assist
- **Notable:** Acquired a commercial medicine and dedicated biologics manufacturing capability in 2018., Raised a USD 60 million Series A in February 2018., Leukine received FDA approval for hematopoietic acute radiation syndrome on March 29, 2018.

## Products & services

- **Leukine (sargramostim)** — GM-CSF immune stimulant used in specified chemotherapy and transplantation settings and to increase survival after myelosuppressive radiation exposure. First FDA approved in 1991; global rights acquired by PTx in 2018.
- **Bizengri (zenocutuzumab-zbco)** — HER2/HER3 bispecific antibody; PTx licensed U.S. commercialization for NRG1 fusion-positive cancer from Merus in 2024. FDA indications cover specified previously treated advanced lung, pancreatic and, from May 2026, bile-duct cancers.
- **Imreplys (sargramostim)** — EU-authorized treatment for hematopoietic acute radiation syndrome, under exceptional circumstances; authorization issued August 21, 2025.
- **PTx Assist** — Patient support and access resources for PTx therapies, subject to program eligibility.

## Achievements

- Acquired a commercial medicine and dedicated biologics manufacturing capability in 2018.
- Raised a USD 60 million Series A in February 2018.
- Leukine received FDA approval for hematopoietic acute radiation syndrome on March 29, 2018.
- U.S. Bizengri license announced immediately before its December 4, 2024 initial FDA approval.
- Imreplys received EU marketing authorization on August 21, 2025.
- FDA approved Bizengri for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026.

## Latest updates

- **2026-07** — PTx announced publication of the eNRGy cholangiocarcinoma cohort in Journal of Clinical Oncology.
- **2026-05** — FDA approved Bizengri for previously treated advanced NRG1 fusion-positive cholangiocarcinoma on May 8.
- **2026-04** — PTx announced a supplemental Bizengri application for NRG1 fusion-positive cholangiocarcinoma.
- **2025-08** — EU marketing authorization issued for Imreplys under exceptional circumstances.

## Links

- Website: https://www.partnertx.com/
- LinkedIn: https://www.linkedin.com/company/partner-therapeutics
- Twitter/X: https://twitter.com/PartnerTx
- Facebook: https://www.facebook.com/partnertherapeutics/

---

Profile page: https://yespress.io/partner-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-10-06